Caplin Point Acquires 10 ANDAs, Bolstering US Injectables & Ophthalmic Portfolio

• Caplin Point acquired 10 approved Abbreviated New Drug Applications (ANDAs) for injectable and ophthalmic products from a multinational manufacturer.
• The acquisition, through Caplin Steriles Ltd. and Caplin One Labs Ltd., strengthens its US market presence, targeting a $473.2 million market.
• The portfolio includes oncology injectables, to be commercialized from the new Kakkalur facility, supporting global expansion.
• Caplin Steriles has 49 US ANDA approvals and a pipeline of over 55 products; Caplin One Labs acquired five of the new ANDAs.
• Caplin Point reported an 18% YoY net profit increase to ₹154.4 crore and 10.6% revenue growth to ₹534 crore for the September quarter.

Why It Matters: Caplin Point's strategic ANDA acquisition significantly expands its US and global regulated market footprint.